// App-Quantinova.ai

Su1413 : Site-Specific Immunomodulation - a Novel Therapeutic Approach for the Management of Crohn's Disease

Researchers

Presenter

  • Simon Sutcliffe

Principal Investigators

  • Kevin P. Bethel

  • Hal Gunn

Medical Centers

  • Freeport Family Wellness Center, Freeport, Bahamas

  • The University of British Columbia, Vancouver, BC, Canada

Locations

  • Canada

  • Bahamas

Companies

  • Qu Biologics Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Crohn's disease

  • Solid malignancies

Biomarkers

  • Cluster of differentiation 69

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • randomized

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved